A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509061-20-00

Acronym

CA027-002

Enrollment

113

Registered

2024-03-20

Start date

2018-11-22

Completion date

2025-12-04

Last updated

2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

Brief summary

Safety: Number and severity of side effects in patients treated with BMS-986253 administered with other medications., Efficacy: Effectiveness of treatment measured by formal response criteria.

Detailed description

The amount of drug present in the body after one or more doses of BMS-986253 administered in combination with other medications., The amount of IL-8 in blood, The length of time during and after treatment that a patient lives with the disease but it does not get worse

Interventions

DRUGanti-IL8 mAb

DRUGIpilimumab

DRUG5% dextrose solution for injection

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUG0.9% sodium chloride solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety: Number and severity of side effects in patients treated with BMS-986253 administered with other medications., Efficacy: Effectiveness of treatment measured by formal response criteria.	—

Secondary

Measure	Time frame
The amount of drug present in the body after one or more doses of BMS-986253 administered in combination with other medications., The amount of IL-8 in blood, The length of time during and after treatment that a patient lives with the disease but it does not get worse	—

Countries

Belgium, France, Germany, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026